Details of the Drug

General Information of Drug (ID: DMDRXLL)

Drug Name

ASP3082

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05382559) A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation. U.S.National Institutes of Health.
2	Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023 Apr;20(4):265-278.